Project data

Funding Entity: European Commission

Call: HORIZON-HLTH-2022-TOOL-11

Coordinator: Fondazione Ebris (Italy)

UNISI Principal Investigator: Prof. Andrea Fagiolini

Department: Department of Molecular and Developmental Medicine (DMMS)

Start date: 1 December 2022

End date: 1 May 2027

 

Description

Major depressive disorders (MDD) affect 280 million people worldwide. Several antidepressants exist. However, very few patients (less than 6 %) benefit from therapeutic methods. The EU-funded OPADE project will identify critical biomarkers that support the decision-making process of healthcare providers by focusing on the microbiota–brain axis, which plays a central role in mental health and MDD. By studying genetics, epigenetics, microbiomes and inflammatory networks to establish patient profiles, the project will predict and optimise antidepressant efficacy. It will also investigate the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune profiling as well as epigenomic and enzymatic algorithms. The project will use the results and analysis to train the artificial intelligence and machine learning predictive tool.

 

Source: CORDIS

 

Project website: https://opade-project.eu/

 

This project has received funding from the European Union’s Horizon 2020 programme under GA No 101095436